Clinical Medicine
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 2020;9:e57278
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299,2020
Differences in presentation and clinical outcomes between left or right bundle branch block and ST segment elevation in patients with acute myocardial infarction.
Meyer MR, Radovanovic D, Pedrazzini G, Rickli H, Roffi M, Rosemann T, Eberli FR, Kurz DJ.
Eur Heart J Acute Cardiovasc Care. 2020
Early life stress determines insulin signaling in adulthood
M. Barton, E.R. Prossnitz
J Physiol 598, 427-428, 2020
Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 292, 201-203, 2020
In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 597, 5731-5737, 2019
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019
Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population.
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T
Clin Ther 41, 107-117, 2019
Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019
HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019
Self-experimentation and serendipity: How cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018
Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 2017 23;147:w14453
Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 18, 168–177, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 23; w14453, 2017
Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017
Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016
Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015
Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015
Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014
Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014
Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014
Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013
Alike but not the same: Anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz
J Cardiovasc Pharmacol 62, 22-25, 2013
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton
IFAVA Scientific Newsletter 75, 1, 2013
Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton
Curr Opin Pharmacol 13, 149-153, 2013
Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton
Curr Opin Lipidol 24, 214-220, 2013
Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton
IFAVA Scientific Newsletter 75, 1, 2013
Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton
Life Sci 91, 528-539, 2012
Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer
Hypertension 59, 1011-1103, 2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin Kidney J 5, 17-27, 2012
Childhood obesity: a life-long health risk
M. Barton
Acta Pharmacol Sin 33, 189-193, 2012
Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012
GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011
Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011
Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012
Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011
Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011
Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009
Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008
Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008
Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007
Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J e-pub, rapid response August 28, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007
Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society , Online Publication Sept 3, 2007
Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg 44, 993-997, 2006
Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.).
Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002
Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000
Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000
Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000
17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998
Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997
Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993
17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993
Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 2020;9:e57278
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299,2020
Differences in presentation and clinical outcomes between left or right bundle branch block and ST segment elevation in patients with acute myocardial infarction.
Meyer MR, Radovanovic D, Pedrazzini G, Rickli H, Roffi M, Rosemann T, Eberli FR, Kurz DJ.
Eur Heart J Acute Cardiovasc Care. 2020
Early life stress determines insulin signaling in adulthood
M. Barton, E.R. Prossnitz
J Physiol 598, 427-428, 2020
Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 292, 201-203, 2020
In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 597, 5731-5737, 2019
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019
Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population.
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T
Clin Ther 41, 107-117, 2019
Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019
HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019
Self-experimentation and serendipity: How cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018
Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 2017 23;147:w14453
Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 18, 168–177, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 23; w14453, 2017
Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017
Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016
Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015
Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015
Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014
Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014
Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014
Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013
Alike but not the same: Anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz
J Cardiovasc Pharmacol 62, 22-25, 2013
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton
IFAVA Scientific Newsletter 75, 1, 2013
Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton
Curr Opin Pharmacol 13, 149-153, 2013
Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton
Curr Opin Lipidol 24, 214-220, 2013
Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton
IFAVA Scientific Newsletter 75, 1, 2013
Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton
Life Sci 91, 528-539, 2012
Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer
Hypertension 59, 1011-1103, 2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin Kidney J 5, 17-27, 2012
Childhood obesity: a life-long health risk
M. Barton
Acta Pharmacol Sin 33, 189-193, 2012
Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012
GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011
Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011
Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012
Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011
Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011
Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009
Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008
Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008
Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007
Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J e-pub, rapid response August 28, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007
Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society , Online Publication Sept 3, 2007
Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg 44, 993-997, 2006
Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.).
Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002
Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000
Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000
Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000
17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998
Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997
Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993
17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993
Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992